Noteworthy Price Action: Time to Buy Aclaris Therapeutics Inc After Today’s Huge Increase?

Noteworthy Price Action: Time to Buy Aclaris Therapeutics Inc After Today's Huge Increase?

The stock of Aclaris Therapeutics Inc (NASDAQ:ACRS) is a huge mover today! The stock increased 7.49% or $2.1 on November 29, hitting $30.14. About 637,032 shares traded hands or 100.22% up from the average. Aclaris Therapeutics Inc (NASDAQ:ACRS) has risen 28.74% since April 26, 2016 and is uptrending. It has outperformed by 23.48% the S&P500.
The move comes after 8 months positive chart setup for the $793.13M company. It was reported on Nov, 29 by We have $31.35 PT which if reached, will make NASDAQ:ACRS worth $31.73 million more.

Analysts await Aclaris Therapeutics Inc (NASDAQ:ACRS) to report earnings on March, 22. They expect $-0.67 EPS, down 139.29% or $0.39 from last year’s $-0.28 per share. After $-0.50 actual EPS reported by Aclaris Therapeutics Inc for the previous quarter, Wall Street now forecasts 34.00% negative EPS growth.

Aclaris Therapeutics Inc (NASDAQ:ACRS) Ratings Coverage

Out of 4 analysts covering Aclaris Therapeutics (NASDAQ:ACRS), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Aclaris Therapeutics has been the topic of 8 analyst reports since November 2, 2015 according to StockzIntelligence Inc. The stock has “Market Perform” rating given by JMP Securities on Friday, September 30. The firm has “Buy” rating given on Monday, November 2 by Jefferies. The company was maintained on Monday, September 19 by Jefferies. The stock has “Buy” rating given by Citigroup on Monday, November 2. On Friday, August 12 the stock rating was maintained by Jefferies with “Buy”. William Blair initiated Aclaris Therapeutics Inc (NASDAQ:ACRS) on Monday, November 2 with “Outperform” rating. The stock of Aclaris Therapeutics Inc (NASDAQ:ACRS) earned “Buy” rating by Guggenheim on Friday, June 10.

According to Zacks Investment Research, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania.”

More news for Aclaris Therapeutics Inc (NASDAQ:ACRS) were recently published by:, which released: “Why Aclaris Therapeutics, Inc. Stock Is Down Today” on November 17, 2016.‘s article titled: “3 Stocks to Watch on Wednesday: Aclaris Therapeutics Inc (ACRS), Agilent …” and published on November 16, 2016 is yet another important article.

ACRS Company Profile

Aclaris Therapeutics, Inc., incorporated on July 13, 2012, is a clinical-stage specialty pharmaceutical company. The Firm is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment